Evidence map›Paper›PMID 40190631›Full record

ArticleRSC advances2025

Unraveling PPARβ/δ nuclear receptor agonists

Sumit Kumar Mandal, Mohammed Muzaffar-Ur-Rehman, Sonakshi Puri, Banoth Karan Kumar, Pankaj Kumar Sharma, Murugesan Sankaranarayanan, P R Deepa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sumit Kumar MandalBiochemistry and Enzyme Biotechnology Laboratory, Department of Biological Sciences, Birla Institute of Technology and Science Pilani Pilani Campus Pilani-333 031 Rajasthan India p20200425@pilani.bits-pilani.ac.in pankajsharma@pilani.bits-pilani.ac.in deepa@pilani.bits-pilani.ac.in.
Mohammed Muzaffar-Ur-RehmanMedicinal Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science Pilani Pilani Campus Pilani-333 031 Rajasthan India p20210457@pilani.bits-pilani.ac.in p20180042@pilani.bits-pilani.ac.in murugesan@pilani.bits-pilani.ac.in.
Sonakshi PuriBiochemistry and Enzyme Biotechnology Laboratory, Department of Biological Sciences, Birla Institute of Technology and Science Pilani Pilani Campus Pilani-333 031 Rajasthan India p20200425@pilani.bits-pilani.ac.in pankajsharma@pilani.bits-pilani.ac.in deepa@pilani.bits-pilani.ac.in.
Banoth Karan KumarMedicinal Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science Pilani Pilani Campus Pilani-333 031 Rajasthan India p20210457@pilani.bits-pilani.ac.in p20180042@pilani.bits-pilani.ac.in murugesan@pilani.bits-pilani.ac.in.
Pankaj Kumar SharmaBiochemistry and Enzyme Biotechnology Laboratory, Department of Biological Sciences, Birla Institute of Technology and Science Pilani Pilani Campus Pilani-333 031 Rajasthan India p20200425@pilani.bits-pilani.ac.in pankajsharma@pilani.bits-pilani.ac.in deepa@pilani.bits-pilani.ac.in.ORCID https://orcid.org/0000-0002-4901-4628
Murugesan SankaranarayananMedicinal Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science Pilani Pilani Campus Pilani-333 031 Rajasthan India p20210457@pilani.bits-pilani.ac.in p20180042@pilani.bits-pilani.ac.in murugesan@pilani.bits-pilani.ac.in.ORCID https://orcid.org/0000-0002-3680-1577
P R DeepaBiochemistry and Enzyme Biotechnology Laboratory, Department of Biological Sciences, Birla Institute of Technology and Science Pilani Pilani Campus Pilani-333 031 Rajasthan India p20200425@pilani.bits-pilani.ac.in pankajsharma@pilani.bits-pilani.ac.in deepa@pilani.bits-pilani.ac.in.ORCID https://orcid.org/0000-0001-9165-5923

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear receptors with a crucial regulatory role in carbohydrate and lipid metabolism and are emerging druggable targets in "metabolic syndrome" (MetS) and cancers. However, there is a need to identify ligands that can activate specific PPAR subtypes, particularly PPARβ/δ, which is less studied compared with other PPAR isoforms (α and γ). Herein, using the drug-repurposing approach, the ZINC database of clinically approved drugs was screened to target the PPARβ/δ receptor through high-throughput-virtual-screening, followed by molecular docking and molecular dynamics (MD) simulation. The top-scoring ligands were subjected to drug-likeness analysis. The hit molecule was tested in an

Identifiers

PMID40190631
PMCPMC11970364

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.